Skip to main navigation Skip to search Skip to main content

Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)

  • Günter Emons*
  • , Grigor Gorchev
  • , Jalid Sehouli
  • , Pauline Wimberger
  • , Anne Stähle
  • , Lars Hanker
  • , Felix Hilpert
  • , Herbert Sindermann
  • , Carsten Gründker
  • , Philipp Harter
  • *Corresponding author for this work
  • Department of Obstetrics and Gynecology
  • Georg August University Göttingen
  • University Hospital Dr. Gregory Stranski
  • Charite - Universitatsmedizin Berlin
  • University of Duisburg-Essen
  • Universitätsklinikum Carl Gustav Carus
  • St. Vincentius Kliniken Karlsruhe
  • University of Kiel
  • Æterna Zentaris GmbH
  • Dr. Horst Schmidt Klinik GmbH
  • Kliniken Essen-Mitte

Abstract

Objectives To evaluate the activity and toxicity of AEZS-108 (Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors. Methods Women with epithelial ovarian, fallopian tube or primary peritoneal cancer, expressing LHRH receptors were eligible for this trial, when they had progression during treatment with a platinum based regimen or within 6 months after receiving a platinum based regimen and a previous taxane treatment. At least one measurable target lesion (RECIST) or CA-125 levels higher than twice the upper limit of normal range (GCIG-criteria) were required. Patients received AEZS-108 (267 mg/m2 equimolar to 76.8 mg/m2 of free doxorubicin) every 3 weeks as a two hour i.v. infusion. Results Fifty-five of 59 (93%) of ovarian cancer samples screened expressed LHRH receptors. 42 patients were enrolled in this study and received at least 1 infusion of AEZS-108 (ITT population). Of these 42 patients 6 (14.3%) had a partial response, 16 (38%) stable disease, 16 (38%) progressive disease and 4 patients were not evaluable. Median time to progression was 12 weeks (95% CI: 8-20 weeks), and median overall survival was 53 weeks (95% CI: 39-73 weeks). Toxicity profile was favorable. Conclusion AEZS-108 has a clinical activity in platinum refractory/resistant ovarian cancer which seems to be comparable to that of pegylated liposomal doxorubicin or to topotecan. Toxicity was comparably low. These data support the concept of a targeted chemotherapy for tumors expressing LHRH receptors.

Original languageEnglish
JournalGynecologic Oncology
Volume133
Issue number3
Pages (from-to)427-432
Number of pages6
ISSN0090-8258
DOIs
Publication statusPublished - 01.01.2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)'. Together they form a unique fingerprint.

Cite this